BioNeutral Group, Inc. Appoints Dr. Donald Goldmann, M.D. to its Scientific Advisory Board

NEWARK, N.J.--(BUSINESS WIRE)--BioNeutral Group, Inc. (OTCBB: BONU), a chemical technology-based Life Science company that intends to commercialize a novel combinational chemistry-based technology, today announced that the Company has appointed Dr. Donald Goldmann, M.D. to the Scientific Advisory Board. BioNeutral Group will be focusing its attention in areas which Dr. Goldmann has considerable expertise including hospital borne infections and bio-preparedness.

“The addition of Dr. Goldmann to our Scientific Advisory Board is an important step for BioNeutral. With his expertise and understanding of the unmet needs in the healthcare arena, Dr. Goldmann will provide us invaluable insight as we launch our new products into the healthcare market.”

Dr. Goldmann is Professor of Pediatrics at Harvard Medical School and Professor of Immunology and Infectious Diseases and Epidemiology at the Harvard School of Public Health. He teaches a Harvard College Freshman Seminar, “The Impact of Infectious Diseases on History and Society.” Dr. Goldmann's work has focused on preventing and controlling hospital-acquired infections. His applied research in the health services arena focuses on quality measurement and improvement, clinical practice guideline development and evaluation, assessment of parental perceptions of care, and patient safety.

Dr. Goldmann served on CDC’s Hospital Infection Control Practices Advisory Committee and chaired the taskforce that developed national guidelines for the use of a glycopeptide antibiotic, vancomycin. He and his colleagues used infection control as a model for quality assessment and improvement in developing countries including Brazil, Thailand, and Indonesia (development of validated methods to assess the structure, processes, and outcomes of infection control programs), Hungary and Poland (training of multidisciplinary QI teams and national surveillance), Colombia (reduction in C-section infections using QI interventions), Russia (national infection control training initiative and center-specific interventions), Ukraine (hospital assessments and microbiology laboratory capacity), Mexico, (use of QI methods to prevent pediatric nosocomial infection) and the Philippines (infection prevention collaborative and a clinical trial of interventions to reduce antibiotic resistance in academic NICUs).

Dr. Donald Goldmann is a graduate of Harvard Medical School. He completed an internship, residency, and fellowship at Massachusetts General Hospital. He served as an Epidemic Intelligence Service Officer of the Centers for Disease Control.

"I am looking forward to working with other members of the Scientific Advisory Board on Ygiene™, which has very interesting and promising properties,” said Dr. Goldmann. “Based on my experience in combating hospital infections, we certainly need compounds with sporicidal activity."

Dr. Andrew Kielbania, Chief Scientist for BioNeutral Group, Inc. stated "The addition of Dr. Goldmann to our Scientific Advisory Board is an important step for BioNeutral. With his expertise and understanding of the unmet needs in the healthcare arena, Dr. Goldmann will provide us invaluable insight as we launch our new products into the healthcare market.”

"We are extremely pleased to welcome Dr. Goldmann as the newest member of our multi-talented and highly credentialed advisory board. He brings with him many years of hands on expert field experience both at the CDC level and from numerous third world countries where the greatest threat of a pandemic would originate. I am confident that he will bring tremendous added value to our already ground breaking technology platforms,” said Stephen J. Browand, President and CEO of BioNeutral Group, Inc.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a novel combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com.

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of BioNeutral Group can be found in the filings of BioNeutral Group with the U.S. Securities and Exchange Commission.